A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence



Status:Terminated
Conditions:Gastrointestinal, Crohns Disease
Therapuetic Areas:Gastroenterology
Healthy:No
Age Range:18 - 99
Updated:4/21/2016
Start Date:November 2010
End Date:December 2014

Use our guide to learn which trials are right for you!

Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease Patients Undergoing Surgical Resection Who Are at Increased Risk of Recurrence

REMICADE (infliximab) is a drug used to treat active Crohn's disease and is being tested in
an experiment to see if it may be useful in preventing relapse of Crohn's disease after
surgical resection. This study will compare the effects (both good and bad) of REMICADE
(infliximab) to those of placebo. Placebo looks like the drug being studied but has no
active ingredients.

The purpose of this study is to assess the effects of REMICADE (infliximab) in preventing
relapse of Crohn's disease after surgical resection. Patients will be assigned to a group
that will initially receive either infliximab or placebo. Each patient who is allowed to
join the study is put into a group by chance (randomly), like flipping a coin. There is a
possibility that patients can receive both the study drug and placebo at different times in
the study. If a patient is initially randomized to receive placebo, and their study doctor
confirms that they have had a return of active Crohn's Disease symptoms, they can receive
infliximab. If a patient is initially randomized to receive infliximab, and their study
doctor confirms that they are experiencing symptoms of Crohn's Disease, they may receive an
increase in their infliximab dose. Infusions will be administered at Week 0 and then every 8
weeks thereafter through Week 200. The study will use a measure of Crohn's Disease activity
that will be evaluated at each visit and at any time the patient has symptoms suggestive of
their disease getting worse in order to capture recurrence. During the study, patients who
meet the study definition of clinical recurrence will be eligible to have a blinded
infliximab dose increase of 5 mg/kg. In other words, patients receiving placebo would
receive infliximab 5 mg/kg, and patients receiving infliximab 5 mg/kg would have a dose
increase to 10 mg/kg. Approximately 175 sites will be utilized, and approximately 290
patients will be enrolled. The interval between the first and last dose of study agent is
200 weeks. The planned duration of study participation is a maximum of 209 weeks (with a
1-week screening period, a 200-week treatment period, and a final study visit at Week 208).
Group I (infliximab infusions): infliximab (5 mg/kg) will be administered by intravenous
(IV) infusion at Week 0 and every 8 weeks thereafter through Week 200. Group II (placebo
infusions): placebo will be administered by IV infusion at Week 0 and every 8 weeks
thereafter through Week 200

Inclusion Criteria:

- Have a documented diagnosis of CD confirmed by endoscopic, histologic and/or
radiologic studies prior to resection or by tissue obtained at resection

- Have undergone an ileocolonic surgical resection

- Patients must also be at an increased risk of recurrence of active CD

- Patients must not have previously discontinued infliximab as a result of tolerability
issues or they must be naive to treatment with infliximab. Provided patients meet the
above criteria pertaining to infliximab, they are eligible to enroll if they received
prior treatment with adalimumab and/or certolizumab

- Patients must undergo screening for HBV

- Baseline CDAI < 200

- Have adequate blood and liver test values

Exclusion Criteria:

- Have a history of latent or active granulomatous infection, including histoplasmosis
or coccidioidomycosis, prior to screening

- Have a chest radiograph within 3 months prior to the first infusion of study agent
that shows a clinically significant abnormality, such as a malignancy or infection,
or any abnormalities suggestive of TB

- Have macroscopically active CD which was not resected at the time of surgery

- Do not meet the criteria for being at an increased risk of postoperative recurrence
of active CD as outlined in the inclusion criteria

- Have evidence of an active infection at the time of randomization or have had a
serious infection not related to CD (e.g., hepatitis, pneumonia, or pyelonephritis),
within 6 months prior to screening

- Have or have had an opportunistic infection (e.g., herpes zoster [shingles],
cytomegalovirus, Pneumocystis carinii, aspergillosis, histoplasmosis, or mycobacteria
other than TB) within 6 months prior to screening

- Have any known malignancy or history of malignancy within the 5-year period prior to
screening (with the exception of squamous or basal cell carcinoma of the skin that
has been completely excised without evidence of recurrence)

- Have any condition that, in the opinion of the investigator, would compromise the
well-being of the patient or the study or prevent the patient from meeting or
performing study requirements.
We found this trial at
63
sites
?
mi
from
Towson, MD
Click here to add this to my saved trials
?
mi
from
Adelaide,
Click here to add this to my saved trials
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
?
mi
from
Asheville, NC
Click here to add this to my saved trials
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
?
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
?
mi
from
Boston, MA
Click here to add this to my saved trials
?
mi
from
Burlington, VT
Click here to add this to my saved trials
?
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Charlotte, North Carolina 28207
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
?
mi
from
Charlottesville, VA
Click here to add this to my saved trials
?
mi
from
Chevy Chase, MD
Click here to add this to my saved trials
?
mi
from
Chicago, IL
Click here to add this to my saved trials
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
?
mi
from
Clive, IA
Click here to add this to my saved trials
?
mi
from
Decatur, GA
Click here to add this to my saved trials
?
mi
from
Durham, NC
Click here to add this to my saved trials
?
mi
from
Gainesville, FL
Click here to add this to my saved trials
?
mi
from
Germantown, TN
Click here to add this to my saved trials
?
mi
from
Glastonbury, CT
Click here to add this to my saved trials
?
mi
from
Grapevine, TX
Click here to add this to my saved trials
?
mi
from
Great Neck, NY
Click here to add this to my saved trials
?
mi
from
Houston, TX
Click here to add this to my saved trials
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
?
mi
from
Iowa City, IA
Click here to add this to my saved trials
?
mi
from
Jacksonville, FL
Click here to add this to my saved trials
?
mi
from
La Jolla, CA
Click here to add this to my saved trials
?
mi
from
Lebanon, NH
Click here to add this to my saved trials
?
mi
from
Lees Summit, MO
Click here to add this to my saved trials
?
mi
from
Lexington, KY
Click here to add this to my saved trials
?
mi
from
Littleton, CO
Click here to add this to my saved trials
?
mi
from
Louisville, KY
Click here to add this to my saved trials
?
mi
from
Macon, GA
Click here to add this to my saved trials
?
mi
from
Madison, WI
Click here to add this to my saved trials
?
mi
from
Miami, FL
Click here to add this to my saved trials
?
mi
from
Middletown, CT
Click here to add this to my saved trials
?
mi
from
Morristown, NJ
Click here to add this to my saved trials
?
mi
from
Naples, FL
Click here to add this to my saved trials
?
mi
from
Nashville, TN
Click here to add this to my saved trials
?
mi
from
New Haven, CT
Click here to add this to my saved trials
?
mi
from
New Orleans, LA
Click here to add this to my saved trials
?
mi
from
New York, NY
Click here to add this to my saved trials
?
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
?
mi
from
Orange, CA
Click here to add this to my saved trials
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
?
mi
from
Plano, TX
Click here to add this to my saved trials
?
mi
from
Plymouth, MN
Click here to add this to my saved trials
?
mi
from
Portland, OR
Click here to add this to my saved trials
?
mi
from
Raleigh, NC
Click here to add this to my saved trials
?
mi
from
Redwood City, CA
Click here to add this to my saved trials
?
mi
from
Richmond, VA
Click here to add this to my saved trials
?
mi
from
Rochester, MN
Click here to add this to my saved trials
?
mi
from
Rochester, NY
Click here to add this to my saved trials
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
?
mi
from
San Diego, CA
Click here to add this to my saved trials
?
mi
from
Seattle, WA
Click here to add this to my saved trials
?
mi
from
Tacoma, WA
Click here to add this to my saved trials
?
mi
from
Troy, MI
Click here to add this to my saved trials
?
mi
from
Weston, FL
Click here to add this to my saved trials
?
mi
from
Winter Park, FL
Click here to add this to my saved trials